Clinical trials: Congenital Cmv
Cytomegalovirus Retinitis, HIV Infections
Comparison of Two Drugs, Cidofovir and Ganciclovir, in Treating Patients With AIDS Who Have CMV Retinitis
To compare cidofovir with a commonly used treatment regimen, ganciclovir given by mouth (oral) and through an eye device (intraocular) , in order to determine the safety and effectiveness of cidofovir in preventing vision loss in…
- Trial name
- NCT00000894
- Testing
- Cidofovir, Probenecid, Ganciclovir
- Where
- 12 sites in United States
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Congenital CMV Infection, Sensorineural Hearing Loss
Long-Term Outcomes of Children With Congenital CMV in New York State
PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen.
- Trial name
- PROACTIVE NYS (NCT06226558)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Stony Brook University
Congenital Cmv
Observational Study of the Management of Infants With Congenital CMV
This is an observational, prospective/retrospective multicentre, cohort study of children diagnosed with cCMV. This study will contribute to a wider study also recruiting participants in Europe and other countries worldwide.
- Trial name
- cCMVnet (NCT05855889)
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- St George's, University of London
Cytomegalovirus Anterior Segment Infection, Anterior Uveitis
Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
Objective of this study is to investigate the intracameral level of ganciclovir following topical application of 0.15% ganciclovir gel (VIRGAN©) for Cytomegalovirus (CMV) anterior uveitis and endothelitis.
- Conditions
- Cytomegalovirus Anterior Segment Infection, Anterior Uveitis, Endotheliitis
- Trial name
- Virgan (NCT01647529)
- Testing
- Ganciclovir
- Where
- Singapore
- Volunteers
- 29 people
- Sponsor
- Singapore National Eye Centre
Cytomegalovirus Infection
Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
The objectives of this study were: 1. To demonstrate the efficacy/safety of a short therapeutic strategy of treatment of CMV infection/disease in SOT patients (kidney, liver and heart recipients) based on 21 days of treatment. 2.
- Trial name
- NCT00730769
- Testing
- Single arm (ganciclovir and valganciclovir)
- Where
- Spain
- Volunteers
- 21 people
- Sponsor
- Salvador Gil-Vernet
Cytomegalovirus Infections, Neurologic Dysfunction
Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection
Cytomegalovirus (CMV) is the most common cause of congenital infection, with approximately 0.5% of pregnant women being infected during pregnancy.
- Trial name
- NCT03188679
- Testing
- amniocentesis
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Cytomegalovirus Congenital Infection
Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Because the potential benefit of standard intravenous immunoglobulins (IVIG) - obtained from unselected donor pools including a varying proportion of donors previously exposed to CMV - has not yet been explored in pregnant women…
- Trial name
- NCT01659684
- Testing
- standard intravenous immunoglobulin
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Fondazione Onlus Camillo De Lellis
Congenital Cytomegalovirus Infection
Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in Utero
The main objective of this study is to validate , in the neonatal period, a prognostic score for the development of neurosensorineural sequelae at 1 year and at 2 years in neonates infected in utero by cytomegalovirus.
- Trial name
- CYMEPEDIA (NCT01923636)
- Testing
- detection of CMV
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Congenital CMV Infection
Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit
Congenital cytomegalovirus (cCMV) is the most common non-genetic cause of pediatric hearing loss and an important cause of neurodevelopmental delay.
- Trial name
- NCT02680743
- Testing
- Education of parents to pursue prompt hearing screening.
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Nebraska
Pregnant Women, CMV Infected Fetuses
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus Valaciclovir
The investigators' hypothesis is that maternal treatment with Letermovir will inhibit fetal CMV replication better than Valaciclovir in infected fetuses and lead to a higher proportion of negative CMV PCR at birth in neonatal…
- Trial name
- CYMEVAL3-step2 (NCT05446571)
- Testing
- Letermovir, Valacyclovir
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
DNA Virus Infection, Herpesviridae Infections
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
Study Phase: IV Study Type: Open-label, multicenter, randomised clinical trial with two arms stratified for an intensified immunosuppressive regimen in patients at high risk for acute rejection.
- Conditions
- DNA Virus Infection, Herpesviridae Infections, Cytomegalovirus Infection
- Trial name
- NCT00373165
- Testing
- Ganciclovir
- Volunteers
- 150 people
- Sponsor
- Lower Saxony Center for Nephrology
Cytomegalovirus Retinitis, HIV Infections
Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS
To evaluate the effect of MSL 109, human monoclonal anti-cytomegalovirus (CMV) antibody, on time to progression of CMV retinitis. To determine the safety and pharmacokinetic profile of MS 109.
- Trial name
- NCT00001061
- Testing
- Sevirumab, Foscarnet sodium, Ganciclovir
- Where
- 20 sites in United States
- Volunteers
- 167 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)